Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
about
The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients.A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinibA comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.Resistance to anticancer drugs permanently alters electrophoretic mobility of cancer cell lines.Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivoThe roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance.Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells.Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells.Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells.Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells.Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts.
P2860
Q34984116-A2D9F695-0057-4E6F-AC0B-AB1734E62EFBQ35040972-890E2039-5588-47BA-8BB0-D76EC6E71E94Q35991845-41DEB898-A614-47B8-BA1F-68C257E0877CQ38718062-A2244CD6-104B-4450-877D-F26DD1B8FFD6Q39010499-FBBF78F5-70A3-4990-BAC4-FF77179E4D50Q39197389-BB300EED-D386-4F98-9275-E4B80995DFAEQ39253571-E665F478-BFB4-408F-849E-CD7BD2DAB8EFQ39404062-81C1A099-D115-4E6B-9966-05356886D1BDQ39506935-3B04D1D0-41C2-45CA-95AA-E2069472F007Q39573963-03F61A75-9E17-4289-91C1-761F85AE6BE8Q39843822-C7C3C1A5-6E73-4BBC-A24C-F5D452903312Q42904735-532E4459-75CE-4978-8BFB-28EC39E4CA1AQ43122174-E5A09B43-A762-4F46-9788-6B75F99719E3Q43173262-5A1940A0-A459-4CF7-B0B1-FD562109FED0
P2860
Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
@en
type
label
Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
@en
prefLabel
Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
@en
P2860
P1433
P1476
Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
@en
P2093
Ali Ugur Ural
Ufuk Gunduz
P2860
P304
P356
10.1080/10245330701384179
P50
P577
2007-12-01T00:00:00Z